Evolus

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evolus reports robust Q4 earnings, eyes international expansion and profitability

Evolus' Q4 2022 performance exceeded expectations, driven by strong revenue growth and customer acquisition.
The company's strategic focus on market share gains, international expansion, and profitability sets a positive trajectory.
Challenges from new competition and market dynamics require strategic responses to maintain leadership.
Opportunities in international expansion, corporate development, and market growth position Evolus for future success.

Evolus secures strategic partnership for growth in dermal filler market

Evolus' strong Q1 performance and strategic partnership with Symatese position the company for significant growth in the dermal filler market.
While facing challenges in safety comparisons and patient demographics, Evolus has opportunities to leverage its unique manufacturing process and upcoming data releases for market advantage.
Overall, Evolus is well-funded, poised for profitability, and focused on differentiating its product line for long-term success.

Evolus (EOLS) exceeds Q2 sales targets, eyes international expansion

Evolus (EOLS) delivered a strong performance in Q2, with accelerated sales growth, efficient cost management, and a focus on profitability, positioning the company for future success.
While facing challenges in market penetration and profitability, Evolus's strategic strengths in customer acquisition, innovation, and financial discipline provide a solid foundation for growth.
With opportunities for revenue expansion, international market growth, and disruptive product launches, Evolus is poised to capitalize on its strengths and address key challenges to drive long-term value for investors.

Evolus (EOLS) achieves record revenue and profitability, eyes global expansion

Evolus (EOLS) delivered a stellar performance in Q3 2023, with record revenue, strong financials, and promising R&D outcomes, positioning the company for continued growth and profitability.
The company's strategic strengths lie in market expansion, brand loyalty, and a clear long-term vision, supported by confidence in achieving ambitious revenue targets and product innovation.
While challenges in market competition and resource optimization persist, Evolus has opportunities in market segments, international expansion, and industry visibility to drive future growth.

Evolus surpasses revenue targets, eyes $700 million goal by 2028

Evolus delivered strong financial performance in Q4 2023, exceeding revenue expectations and achieving profitability. With a strategic focus on market expansion, product differentiation, and customer engagement, the company aims to reach a revenue target of $700 million by 2028.

Evolus reports robust Q1 growth, eyes $700M revenue target by 2028

Evolus demonstrated strong financial performance and market expansion in Q1 2024, with a focus on operational efficiency and customer engagement. The company's strategic goals include achieving profitability by year-end and targeting substantial revenue growth by 2028.
While facing challenges in market dynamics and profitability targets, Evolus remains optimistic about its competitive position and growth prospects. Opportunities lie in leveraging loyalty programs, expanding internationally, and launching new product lines to drive future success.

Evolus reports profitable Q2, eyes global expansion and new products

Evolus demonstrated strong performance in Q2 2024, achieving profitability and revenue growth.
The company's focus on innovation, international expansion, and financial management positions it for future success.
Challenges lie in maintaining growth momentum, executing expansion plans, and managing costs effectively.
Opportunities include capitalizing on market demand, global expansion, product innovation, and financial optimization.

Evolus reports strong Q3 growth, eyes $700M revenue target

Evolus showcased robust growth and strategic initiatives in Q3 2024, aiming for significant revenue targets by 2028. While facing revenue challenges and market competition, the company's strengths in product innovation and market expansion offer opportunities for sustained growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEWPORT BEACH, Calif., April  16, 2020  (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced a pre-emptive plan to support the U.S. aesthetic neurotoxin market in light of the COVID-19 pandemic.

Evolus Provides Strategic Business Update

Company Remains Confident in its Intellectual Property and the Overall Merits of the Case Company Remains Confident in its Intellectual Property and the Overall Merits of the Case

Evolus Provides Update on International Trade Commission (ITC) Case

Evolus, Inc. (EOLS) CEO David Moatazedi on Q4 2019 Results - Earnings Call Transcript

Primary Endpoint of Non-Inferiority Achieved with Responder Rates* of 65.02% for PrabotulinumtoxinA and 62.56% for OnabotulinumtoxinA at Week 4 Primary Endpoint of Non-Inferiority Achieved with Responder Rates* of 65.02% for PrabotulinumtoxinA and 62.56% for OnabotulinumtoxinA at Week 4

Positive Results from Phase III, Split-Face, Head-to-Head Study Comparing OnabotulinumtoxinA and PrabotulinumtoxinA in the Treatment of Crow’s Feet Lines Published in Dermatologic Surgery

Evolus: A Wrinkle For Botox

Evolus: Much Better Than Expected

Evolus, Inc. (EOLS) CEO David Moatazedi on Q3 2019 Results - Earnings Call Transcript

NEWPORT BEACH, Calif. and CAMBRIDGE, Ontario, Oct.  16, 2019  (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS) and Clarion Medical Technologies, a leading Canadian provider of medical and aesthetic equipment and consumables, today announced the first shipment of Nuceiva™ (prabotulinumtoxinA) in Canada. Nuceiva™ is a 900 kDa purified botulinum toxin type A formulation that is approved by Health Canada for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients < 65 years of age.

Evolus and Clarion Medical Technologies Announce First Shipment of Nuceiva™ (prabotulinumtoxinA) to Customers in Canada

NEWPORT BEACH, Calif., Oct.  01, 2019  (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that the European Commission (EC) has approved the marketing of Nuceiva™ (prabotulinumtoxinA). Similar to other neurotoxins marketed in Europe, Nuceiva™ is approved for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the facial lines has an important psychological impact in adults below 65 years of age. The EC decision is applicable to all 28 European Union member states plus Iceland, Norway and Liechtenstein. 

Evolus Receives Approval for Nuceiva™ in the European Union

NEWPORT BEACH, Calif., Sept.  18, 2019  (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in the 2019 Cantor Global Healthcare Conference in New York, NY.

Evolus will Participate in Cantor Global Healthcare Conference

Jeuveau® Achieves Number Three Unit Share Position1 in the U.S. Within 90 Days of Launch

Evolus Announces Successful Completion of the Jeuveau® Experience Treatment (J.E.T) Program

Evolus, Inc. (EOLS) CEO David Moatazedi on Q2 2019 Results - Earnings Call Transcript

Canopy Growth

DexCom

GW Pharmaceuticals

Here we discuss four medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

4 Medical Product Stocks Set to Beat This Earnings Season

As of late, it has definitely been a great time to be an investor Evolus.

Will Evolus Continue to Surge Higher?

The price slipped on news of a share offering by one of its biggest investors.

Here's Why Evolus Stock Tumbled 17.4% Today

Evolus, Inc. (EOLS) CEO David Moatazedi on Q1 2019 Results - Earnings Call Transcript

Extreme Networks

Shockwave Medical

These three health and technology stocks are seeing technical strength ahead of upcoming earnings.

3 Stocks To Watch Ahead Of Earnings

Blueprint Medicines

REGENXBIO

These under-the-radar stocks could be poised to make big moves in the coming months.

3 Small-Cap Biotech Stocks to Watch Now

Merger and acquisition moves played a role in the declines for two of these stocks.

Why Evolus Slumped Today

There are no frown lines from investors as the company is about to launch a competitor to Botox.

Why Evolus Stock Is Soaring 12% Higher Today

Evolus, Inc. (EOLS) CEO David Moatazedi on Q4 2018 Results - Earnings Call Transcript

News for Evolus Stock (EOLS)